All In Biotech

Drug Trial Radar · NCT01278342

Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic Patients

An Open-label, Two-step, Multicenter European Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic Patients Not Adequately Controlled by Conventional Regimen

Last checked: Nov 20, 2026Latest source record: Mar 3, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

70

Actual

Start

Sep 2006

Primary completion

Nov 2009

Study completion Nov 2009

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Jan 17, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will assess the efficacy of 8 months treatment of Sandostatin® LAR® High Dose monotherapy or Sandostatin® LAR® High Dose in combination either with growth hormone antagonist or dopamine agonist to control biochemical parameters (GH and insulin-like growth factor I \[IGF I\]) of acromegalic patients not achieving biochemical normalization at conventional regimen.

Conditions

  • Acromegaly

Interventions

  • Sandostatin LARDrug

    40 mg intramuscular (i.m.) every 28 days for 3 months

  • pegvisomantDrug

    Weekly doses of pegvisomant 70 mg subcutaneously (s.c.) for 4 months given with Sandostatin LAR 40 mg intramuscular (i.m.) every 28 days for 4 months

  • cabergolineDrug

    Weekly cabergoline for 4 months, with weekly doses of Sandostatin LAR 40 mg intramuscular (i.m.) every 28 days for 4 months. Cabergoline doses as follows: 1. st week: 0.25 mg twice a week (0.50 mg/week) 2. nd week: 0.50 mg/week twice a week (1 mg/week) 3. rd week: 0.50 mg four times a week (2 mg/week) 4. th week: 0.50 mg daily (3.5 mg/week) Subsequent 3 months: 0.50 mg daily (3.5 mg/week)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The Percentage of Participants With Complete Response (CR) at 8 MonthsTime frame: From Baseline to 8 months

Locations

20 sites in 5 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Brest, France

  • Novartis Investigative Site

    Bron, France

  • Novartis Investigative Site

    Le Kremlin-Bicêtre, France

  • Novartis Investigative Site

    Nice, France

  • Novartis Investigative Site

    Nîmes, France

  • Novartis Investigative Site

    Pessac, France

  • Novartis Investigative Site

    Toulouse, France

  • Novartis Investigative Site

    Genova, Italy

  • Novartis Investigative Site

    Naples, Italy

  • Novarts Investigative Site

    Naples, Italy

  • Novartis Investigative Site

    Padova, Italy

  • Novartis Investigative Site

    Perugia, Italy

  • Novartis Investigative Site

    Pisa, Italy

  • Novartis Investigative Site

    Torino, Italy

  • Novartis Investigative Site

    Lodz, Poland

  • Novartis Investigative Site

    Warsaw, Poland

  • Novartis Investigative Site

    Wroclaw, Poland

  • Novartis Investigative Site

    Zabrze, Poland

  • Novartis Investigative Site

    Porto, Portugal

  • Novartis Investigative Site

    Lausanne, Switzerland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.